Vericiguat preserved cardiac function and mitochondrial quality in a rat model of mitral regurgitation.

Aims: New drugs for heart failure (HF) that target restoring the impaired NO-sGC-cGMP pathway are being developed. We aimed to investigate the effects of vericiguat, an sGC stimulator, on cardiac function, blood pressure (BP), cardiac mitochondrial quality, and cardiac fibrosis in rat models of chronic mitral regurgitation (MR).

Materials And Methods: We surgically induced MR in 20 Sprague-Dawley rats and performed sham procedures on 10 rats (negative control).